
It may be the “front page of the internet” but Roth analyst Rohit Kulkarni says investors should not be looking at Reddit (Reddit Stock Quote, Chart, News, Analysts, Financials NYSE:RDDT) right now.
In a research update to clients January 22, the analyst said RDDT, a stock that has been on a tear of late, was now fully valued.
“We are downgrading our rating on RDDT shares to Neutral from Buy as we believe the near-term risk/reward is fairly balanced at current levels,” he wrote. “We are raising our estimates and our PT goes to $195 based on 20x ’25E Revs and implies 46x ’26E EBITDA. Since going public in Mar ’24 at $34 IPO price, Reddit shares have gone up ~450% (vs. S&P 500 +15%) driven by a ~40% uptick in estimates and +310% in EV/Rev multiple.”
In the research update, Kulkarni, as mentioned raised his price target significantly -from $116.00 to $195.00, but downgraded Reddit from “Buy” to “Neutral”.
The analyst thinks the company will post EBITDA of $292.2-million on revenue of $1.29-billion in fiscal 2024. He expects those numbers will improve to EBITDA of $549.0-million on revenue of $1.88-billion in fiscal 2025.
Aside from the valuation, the analyst addressed the reasons behind the downgrade.
“#1. 2025 fundamental optics mixed at best: Reddit revenues accelerated from 21% YoY in 2023 to >60% in 2024E while growing EBITDA margins from -9% in 2023 to >20% in 2024E. Over the next 12 months, we expect revenue growth to decelerate every quarter with somewhat deteriorating incremental EBITDA margins; #2. User growth comps are tough in 1H25: Reddit added record number of QoQ users in 2024, partially driven by a perfect combo of benign Google (GOOGL-Buy) algo changes and favorable user funnel changes. We are afraid that replicating 2024 conditions might require more than a prayer; and #3. Incremental margins could come under pressure: We believe RDDT mgmt. would reinvest revenue upside into growth opportunities as 2025 progresses, effectively lowering incremental margin profile this year,” Kulkarni concluded.
Comment